搜索结果：Pharmaceutical development and technology

In the last few years there has been a huge progress in a development of printing techniques and their application in pharmaceutical sciences and particularly in the pharmaceutical technology. The variety of printing methods makes it necessary to systemize them, explain the principles of operation, and specify the possibilities of their use in pharmaceutical technology. This paper aims to review the printing techniques used in a drug development process. The growing interest in 2D and 3D printing methods results in continuously increasing number of scientific papers. Introduction of the first printed drug Spritam@ to the market seems to be a milestone of the 3D printing development. Thus, a particular aim of this review is to show the latest achievements of the researchers in the field of the printing medicines.

Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic knowledge and provides expedited solutions to complex challenges. Remarkable advancements in AI technology and machine learning present a transformative opportunity in the drug discovery, formulation, and testing of pharmaceutical dosage forms. By utilizing AI algorithms that analyze extensive biological data, including genomics and proteomics, researchers can identify disease-associated targets and predict their interactions with potential drug candidates. This enables a more efficient and targeted approach to drug discovery, thereby increasing the likelihood of successful drug approvals. Furthermore, AI can contribute to reducing development costs by optimizing research and development processes. Machine learning algorithms assist in experimental design and can predict the pharmacokinetics and toxicity of drug candidates. This capability enables the prioritization and optimization of lead compounds, reducing the need for extensive and costly animal testing. Personalized medicine approaches can be facilitated through AI algorithms that analyze real-world patient data, leading to more effective treatment outcomes and improved patient adherence. This comprehensive review explores the wide-ranging applications of AI in drug discovery, drug delivery dosage form designs, process optimization, testing, and pharmacokinetics/pharmacodynamics (PK/PD) studies. This review provides an overview of various AI-based approaches utilized in pharmaceutical technology, highlighting their benefits and drawbacks. Nevertheless, the continued investment in and exploration of AI in the pharmaceutical industry offer exciting prospects for enhancing drug development processes and patient care.

The Technology Readiness Level (TRL) scale was initially developed by NASA in the 1970s and is now widely used in space, nuclear, and other complex technology sectors in the US and beyond. The TRL scale is particularly useful for determining where extrapolation of untested sub-systems or features could produce technical risk, cause expensive redesigns, or act as a roadblock to technology development. In this paper, we propose the development of a sociotechnical readiness level (SRL), premised on the understanding that the successful development and eventual use of a technology requires achieving not only full technological readiness but also anticipating, prioritizing, and addressing societal concerns that may arise during the course of development of a technology. Failures to anticipate and address societal factors in the early stages of technology development have led to high-profile delays and, in some cases, ultimate failures of nuclear technology projects. The sociotechnical readiness scale, which conceptually draws on the design research and science and technology studies scholarship, centers on principles of equity and environmental justice in technology design, and emphasiz

The subject of crystal engineering started in the 1970s with the study of topochemical reactions in the solid state. A broad chemical definition of crystal engineering was published in 1989, and the supramolecular synthon concept was proposed in 1995 followed by heterosynthons and their potential applications for the design of pharmaceutical cocrystals in 2004. This review traces the development of supramolecular synthons as robust and recurring hydrogen bond patterns for the design and construction of supramolecular architectures, notably, pharmaceutical cocrystals beginning in the early 2000s to the present time. The ability of a cocrystal between an active pharmaceutical ingredient (API) and a pharmaceutically acceptable coformer to systematically tune the physicochemical properties of a drug (i.e., solubility, permeability, hydration, color, compaction, tableting, bioavailability) without changing its molecular structure is the hallmark of the pharmaceutical cocrystals platform, as a bridge between drug discovery and pharmaceutical development. With the design of cocrystals via heterosynthons and prototype case studies to improve drug solubility in place (2000-2015), the period between 2015 to the present time has witnessed the launch of several salt-cocrystal drugs with improved efficacy and high bioavailability. This review on the design, synthesis, and applications of pharmaceutical cocrystals to afford improved drug products and drug substances will interest researchers in crystal engineering, supramolecular chemistry, medicinal chemistry, process development, and pharmaceutical and materials sciences. The scale-up of drug cocrystals and salts using continuous manufacturing technologies provides high-value pharmaceuticals with economic and environmental benefits.

Pharmaceutical research and development has accumulated vast and heterogeneous archives of data. Much of this knowledge stems from discontinued programs, and reusing these archives is invaluable for reverse translation. However, in practice, such reuse is often infeasible. In this work, we introduce DiscoVerse, a multi-agent co-scientist designed to support pharmaceutical research and development at Roche. Designed as a human-in-the-loop assistant, DiscoVerse enables domain-specific queries by delivering evidence-based answers: it retrieves relevant data, links across documents, summarises key findings and preserves institutional memory. We assess DiscoVerse through expert evaluation of source-linked outputs. Our evaluation spans a selected subset of 180 molecules from Roche's research and development repositories, encompassing over 0.87 billion BPE tokens and more than four decades of research. To our knowledge, this represents the first agentic framework to be systematically assessed on real pharmaceutical data for reverse translation, enabled by authorized access to confidential archives covering the full lifecycle of drug development. Our contributions include: role-specialized

Drug development is becoming more and more complex and resource-intensive. To reduce the costs and the time-to-market, the pharmaceutical industry employs cutting-edge automation solutions. Supportive robotics technologies, such as stationary and mobile manipulators, exist in various laboratory settings. However, they still lack the mobility and dexterity to navigate and operate in human-centered environments. We evaluate the feasibility of quadruped robots for the specific use case of remote inspection, utilizing the out-of-the-box capabilities of Boston Dynamics' Spot platform. We also provide an outlook on the newest technological advancements and the future applications these are anticipated to enable.

The pharmaceutical industry has experienced increasing costs and sustained high attrition rates in drug development over the last years. One proposal that addresses this challenge from a statistical perspective is the use of quantitative decision-making (QDM) methods to support a data-driven, objective appraisal of the evidence that forms the basis of decisions at different development levels. Growing awareness among statistical leaders in the industry has led to the creation of the European EFSPI/PSI special interest group (ESIG) on quantitative decision making to share experiences, collect best practices, and promote the use of QDM. In this paper, we introduce key components of QDM and present examples of QDM methods on trial, program, and portfolio level. The ESIG created a questionnaire to learn how and to what extent QDM methods are currently used in the different development phases. We present the main questionnaire findings, and we show where QDM is already used today but also where areas for future improvement can be identified. In particular, statisticians should increase their visibility, involvement, and leadership in cross-functional decision-making.

As belief around the potential of computational social science grows, fuelled by recent advances in machine learning, data scientists are ostensibly becoming the new experts in education. Scholars engaged in critical studies of education and technology have sought to interrogate the growing datafication of education yet tend not to use computational methods as part of this response. In this paper, we discuss the feasibility and desirability of the use of computational approaches as part of a critical research agenda. Presenting and reflecting upon two examples of projects that use computational methods in education to explore questions of equity and justice, we suggest that such approaches might help expand the capacity of critical researchers to highlight existing inequalities, make visible possible approaches for beginning to address such inequalities, and engage marginalised communities in designing and ultimately deploying these possibilities. Drawing upon work within the fields of Critical Data Studies and Science and Technology Studies, we further reflect on the two cases to discuss the possibilities and challenges of reimagining computational methods for critical research in

Section 1 Principles of dosage form design and development: introduction to drugs and pharmacy new drug development and approval process dosage form design - pharmaceutic and formulation consideration dosage form design - biopharmaceutic and pharmacokinetics considerations current good manufacturing practices and good compounding practices. Section 2 Solid dosage forms and modified-release drug delivery systems: powders and granules capsules and tables modified-release dosage forms and drug delivery systems. section 3 Semi-solid and transdermal systems: ointments, creams, and gels transdermal drug delivery systems, Section 4 Pharmaceutical inserts: suppositories and inserts. Section 5 Liquid dosage forms: solutions disperse systems. Section 6 Sterile dosage forms and delivery systems: parenteral biological ophthalmic solutions and suspensions. Section 7 Novel and advanced dosage forms, delivery systems, and devices: radiopharmaceuticals products of biotechnology novel dosage forms and drug delivery technology. Appendix: systems and techniques of pharmaceutical measurement.

There are significant differences in innovation performance between countries. Additionally, the pharmaceutical sector is stronger in some countries than in others. This suggests that the development of the pharmaceutical industry can influence a country's innovation performance. Using the Global Innovation Index and selected performance measures of the pharmaceutical sector, this study examines how the pharmaceutical sector influences the innovation performance of countries from the European context. The dataset of 27 European countries was analysed using simple, and multiple linear regressions and Pearson correlation. Our findings show that only three indicators of the pharmaceutical industry, more precisely pharmaceutical Research and Development, pharmaceutical exports, and pharmaceutical employment explain the innovation performance of a country largely. Pharmaceutical Research and Development and exports have a significant positive impact on a country's innovation performance, whereas employment in the pharmaceutical industry has a slightly negative impact. Additionally, global innovation performance has been found to positively influence life expectancy. We further outline t

The advent of 3D printing has transformed the pharmaceutical industry, enabling precision drug manufacturing with controlled release profiles, dosing, and structural complexity. Additive manufacturing (AM) addresses the growing demand for personalized medicine, overcoming limitations of traditional methods. This technology facilitates tailored dosage forms, complex geometries, and real-time quality control. Recent advancements in drop-on-demand printing, UV curable inks, material science, and regulatory frameworks are discussed. Despite opportunities for cost reduction, flexibility, and decentralized manufacturing, challenges persist in scalability, reproducibility, and regulatory adaptation. This review provides an in-depth analysis of the current state of AM in pharmaceutical manufacturing, exploring recent developments, challenges, and future directions for mainstream integration.

This paper introduces a new process that integrates inventive problem-solving methods into modern software development. The central research question addresses how tech startups can enhance their software development processes with minimal project management expertise. The Systematic Innovation Mounted Software Development Process, which blends Agile and Systematic Innovation, offers an alternative framework to facilitate idea generation in software products. This intuitive project management framework empowers technology-driven companies to manage their projects more effectively. The study aims to provide guidelines for entrepreneurs to manage projects successfully. By collaborating with the existing Agile model, the Systematic Innovation model fosters creativity and innovative problem-solving. Ultimately, this new software development process and its techniques have the potential to significantly impact the software industry, particularly for startups, as they alleviate managerial burdens and allow companies to focus on their core technologies.

In today's world, many technologically advanced countries have realized that real power lies not in physical strength but in educated minds. As a result, every country has embarked on restructuring its education system to meet the demands of technology. As a country in the midst of these developments, we cannot remain indifferent to this transformation in education. In the Information Age of the 21st century, rapid access to information is crucial for the development of individuals and societies. To take our place among the knowledge societies in a world moving rapidly towards globalization, we must closely follow technological innovations and meet the requirements of technology. This can be achieved by providing learning opportunities to anyone interested in acquiring education in their area of interest. This study focuses on the advantages and disadvantages of internet-based learning compared to traditional teaching methods, the importance of computer usage in internet-based learning, negative factors affecting internet-based learning, and the necessary recommendations for addressing these issues. In today's world, it is impossible to talk about education without technology or te

Taste is one of the most important parameters governing patient compliance. Undesirable taste is one of several important formulation problems that are encountered with certain drugs. Oral administration of bitter drugs with an acceptable degree of palatability is a key issue for health care providers, especially for pediatric patients. Several oral pharmaceuticals, numerous food and beverage products, and bulking agents have unpleasant, bitter-tasting components. So, any pharmaceutical formulation with a pleasing taste would definitely be preferred over a competitor's product and would translate into better compliance and therapeutic value for the patient and more business and profits for the company. The desire of improved palatability in these products has prompted the development of numerous formulations with improved performance and acceptability. This article reviews the earlier applications and methodologies of taste masking and discusses the most recent developments and approaches of bitterness reduction and inhibition for oral pharmaceuticals.

Quantum technology is an emergent and potentially disruptive discipline, with the ability to affect many human activities. Quantum technologies are dual-use technologies, and as such are of interest to the defence and security industry and military and governmental actors. This report reviews and maps the possible quantum technology military applications, serving as an entry point for international peace and security assessment, ethics research, military and governmental policy, strategy and decision making. Quantum technologies for military applications introduce new capabilities, improving effectiveness and increasing precision, thus leading to `quantum warfare', wherein new military strategies, doctrines, policies and ethics should be established. This report provides a basic overview of quantum technologies under development, also estimating the expected time scale of delivery or the utilisation impact. Particular military applications of quantum technology are described for various warfare domains (e.g. land, air, space, electronic, cyber and underwater warfare and ISTAR -- intelligence, surveillance, target acquisition and reconnaissance), and related issues and challenges ar

We recount in this essay the decade-long story of Gram Vaani, a social enterprise with a vision to build appropriate ICTs (Information and Communication Technologies) for participatory media in rural and low-income settings, to bring about social development and community empowerment. Other social enterprises will relate to the learning gained and the strategic pivots that Gram Vaani had to undertake to survive and deliver on its mission, while searching for a robust financial sustainability model. While we believe the ideal model still remains elusive, we conclude this essay with an open question about the reason to differentiate between different kinds of enterprises - commercial or social, for-profit or not-for-profit - and argue that all enterprises should have an ethical underpinning to their work.

OBJECTIVES: Drug pipelines are becoming increasingly difficult to formulate. This is punctuated by both retrospective and prospective analyses that show that while 40% of currently marketed drugs are poorly soluble based on the definition of the biopharmaceutical classification system (BCS), about 90% of drugs in development can be characterized as poorly soluble. Although a number of techniques have been suggested for increasing oral bioavailability and for enabling parenteral formulations, cyclodextrins have emerged as a productive approach. This short review is intended to provide both some basic science information as well as data on the ability to develop drugs in cyclodextrin-containing formulations. KEY FINDINGS: There are currently a number of marketed products that make use of these functional solubilizing excipients and new product introduction continues to demonstrate their high added value. The ability to predict whether cyclodextrins will be of benefit in creating a dosage form for a particular drug candidate requires a good working knowledge of the properties of cyclodextrins, their mechanism of solubilization and factors that contribute to, or detract from, the biopharmaceutical characteristics of the formed complexes. SUMMARY: We provide basic science information as well as data on the development of drugs in cyclodextrin-containing formulations. Cyclodextrins have emerged as an important tool in the formulator's armamentarium to improve apparent solubility and dissolution rate for poorly water-soluble drug candidates. The continued interest and productivity of these materials bode well for future application and their currency as excipients in research, development and drug product marketing.

In materials and pharmaceutical development, rapidly and accurately determining the similarity between X-ray powder diffraction (XRPD) measurements is crucial for efficient solid form screening and analysis. We present SMolNet, a classifier based on a Siamese network architecture, designed to automate the comparison of XRPD patterns. Our results show that training SMolNet on loss functions from the self-supervised learning domain yields a substantial boost in performance with respect to class separability and precision, specifically when classifying phases of previously unseen compounds. The application of SMolNet demonstrates significant improvements in screening efficiency across multiple active pharmaceutical ingredients, providing a powerful tool for scientists to discover and categorize measurements with reliable accuracy.

The increased usage of the information technologies in everyday life and especially in education leads to demands for new forms of teaching, studying and appropriate examination and evaluation of acquired knowledge and skills of the students. Modern electronic educational systems use only those technologies that improve the learning process and make it more effective. The interactive education provides an opportunity to develop skills for independent literature research and activation of the cognitive activity. In this work, it is shown how a modern electronic education is implemented in the curriculum of English language pharmaceutical students at the Medical University - Plovdiv in the course of Information Technologies. It is developed a methodological approach of a hybrid system, i.e. a compulsory attendance at lectures in combination with two different types of conduction of the final test for comparison - a paper-based test and a remote web-based one. The results received from the parallel tests are processed and analysed and the conclusions are used to enhance the quality of the developed test and the type of implementation. Moreover, the examined students fill in an anonymo